Literature DB >> 19530074

Biphasic flux profiles of melatonin: the Yin-Yang of transdermal permeation enhancement mediated by fatty alcohol enhancers.

Karunya K Kandimalla1, R J Babu, M Singh.   

Abstract

This study investigates physicochemical processes responsible for the biphasic transdermal flux profiles of melatonin in the presence of saturated fatty alcohols (SFAL) and unsaturated fatty alcohols (USFAL). The first phase melatonin flux (J(1st)) in the presence of USFAL enhancers increased with increase in the number of double bonds and reached a limiting value with two double bonds in the molecule. In case of SFAL enhancers, J(1st) increased with enhancer chain length and log formulation/skin partition coefficients (log Ps), which were calculated using the solubility parameters of various formulation components. But, melatonin flux in the second phase decreased with increase in the enhancer chain length and log P values. On the other hand, the transepidermal water loss (TEWL) from the SFAL treated skin increased drastically in the second phase and correlated with log P value of the enhancer. High TEWL value, indicative of a severely disrupted SC, may help the polar formulation components to accumulate in the SC. As a consequence, the SC polarity could change significantly and reduce the partitioning of lipophilic enhancer and/or melatonin in the second phase. This study demonstrated that an optimal level of barrier disruption enhances the transdermal permeation of drugs, whereas, a drastic barrier disruption impedes transdermal transport.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19530074      PMCID: PMC2885960          DOI: 10.1002/jps.21812

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

1.  Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution.

Authors:  T W Fischer; C Greif; J W Fluhr; W Wigger-Alberti; P Elsner
Journal:  Skin Pharmacol Physiol       Date:  2004 Jul-Aug       Impact factor: 3.479

2.  The effect of vehicle on the diffusion of salicylic acid through hairless mouse skin.

Authors:  K B Sloan; K G Siver; S A Koch
Journal:  J Pharm Sci       Date:  1986-08       Impact factor: 3.534

3.  Use of solubility parameters of drug and vehicle to predict flux through skin.

Authors:  K B Sloan; S A Koch; K G Siver; F P Flowers
Journal:  J Invest Dermatol       Date:  1986-08       Impact factor: 8.551

4.  Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin.

Authors:  S Andega; N Kanikkannan; M Singh
Journal:  J Control Release       Date:  2001-11-09       Impact factor: 9.776

5.  Effect of barrier disruption by acetone treatment on the permeability of compounds with various lipophilicities: implications for the permeability of compromised skin.

Authors:  J C Tsai; H M Sheu; P L Hung; C L Cheng
Journal:  J Pharm Sci       Date:  2001-09       Impact factor: 3.534

6.  Extended Hildebrand solubility approach: sulfonamides in binary and ternary solvents.

Authors:  A Martin; P L Wu; T Velasquez
Journal:  J Pharm Sci       Date:  1985-03       Impact factor: 3.534

7.  Skin permeation enhancement effect and skin irritation of saturated fatty alcohols.

Authors:  N Kanikkannan; Mandip Singh
Journal:  Int J Pharm       Date:  2002-11-06       Impact factor: 5.875

8.  Formulation and in vitro evaluation of transdermal patches of melatonin.

Authors:  N Kanikkannan; S Andega; S Burton; R J Babu; Mandip Singh
Journal:  Drug Dev Ind Pharm       Date:  2004-02       Impact factor: 3.225

9.  Use of theoretical partition coefficients determined from solubility parameters to predict permeability coefficients for 5-fluorouracil.

Authors:  E F Sherertz; K B Sloan; R G McTiernan
Journal:  J Invest Dermatol       Date:  1987-08       Impact factor: 8.551

10.  Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro.

Authors:  L Kikwai; N Kanikkannan; R J Babu; Mandip Singh
Journal:  J Control Release       Date:  2002-10-04       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.